Clinical Trials · NCT04037254

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Name: Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 1/Phase 2Gonadorelin

Phase: Phase 1/Phase 2
Recruitment status: Completed
Sponsor: NRG Oncology
Enrollment: 22
Start date: Oct 2019
Locations: 95 sites, United States, Canada
Primary endpoint: Number of Participants Disease-free Until Completion of Treatment (2 Years From Start of ADT)

View Gonadorelin compound reference